Oncotarget is focused to addressing of therapy of age-related diseases by slowing down the aging process. Aging brings about age-related diseases such as cardiovascular diseases and stroke, atherosclerosis and hypertension, osteoporosis, prostate enlargement and prostate cancer, seborrhoeic keratosis and scin cancer, type II diabetes and diabetic retinopathy, macular degeneration, Alzheimer's and Parkinsons's diseases. Currently, each disease is treated separately. Yet, even if one disease (such as cancer) would be cured by chemotherapy, other diseases (such as atherosclerosis) will limit life span. Despite increase of the average life expectancy, the maximal human life span has remained unchanged. Yet, all diseases of aging share a common basis - aging. To delay and successfully treat all age-related diseases, it is necessary to inhibit or to slow down the aging process per se. However, as summarized just recently, there was no known intervention that can slow the human aging process. As a medical breakthrough, the antiaging potential of a currently available drug rapamycin become evident (Blagosklonny, 2006, 2007). Recent discoveries revealed the TOR signalling pathway involved in aging. Genetic inhibition of the TOR pathway extends life span in diverse organisms from yeast to mammals. Remarkably, rapamycin, an inhibitor of TOR, is a well tolerated drug approved for renal-transplant patients. The TOR pathway is involved in both cell senescence and age-related diseases. Inhibition of aging will revolutionaze therapy of age-related diseases and will increase healthy life span. The company is focused on the development of: Rapamycin-containing skin cream for therapy of age-related skin diseases and conditions (seborrhoeic keratosis, lichenoid keratosis, other forms of keratoses, psoriasis, psoriasifirm dermatitis, pigmentary changes of the aging skin, hyperproliferation, skin thickness, kelloids, and skin cancers). Prospect focuses will be: 1. Rapamycin-based formulations for therapy of age-related diseases. 2. Development of anti-aging agents for systemic use to slow down aging and increase longevity. 3. Screening of drug libraries and natural products and the discovery of inhibitors of the TOR pathway to be used for anti-aging applications 4. Development of anti-aging agents for systemic use to slow down aging and increase longevity
